Submission Details

RAL-THA-c9f97604
Molecule(s):
O=C(Nc1cncc2ccccc12)[C@H]1c2cc(Cl)ccc2[C@H]2CC[C@@H]1O2

RAL-THA-c9f97604-1

O=C(Nc1cncc2ccccc12)[C@H]1c2cc(Cl)ccc2[C@H]2CC[C@@H]1O2

3-aminopyridine-like Check Availability on Manifold View
O=C(Nc1cncc2ccccc12)[C@H]1c2cc(Cl)ccc2[C@@H]2OC[C@H]1O2

RAL-THA-c9f97604-2

O=C(Nc1cncc2ccccc12)[C@H]1c2cc(Cl)ccc2[C@@H]2OC[C@H]1O2

3-aminopyridine-like Check Availability on Manifold View
Design Rationale:

See EDJ-MED-e4b030d8 and RAL-THA-f8a0f917-3. Enforcing rigidity in the fused aliphatic ring and bias amide into axial position . NOTE: bicyclic acetal may be readily accessible via the corresponding acyclic aldehyde/diol. Such bridged bicyclic acetals can be remarkably stable, case in point: Pfizer's SGLT2 inhibitor ertugliflozin.

Inspired By:
Discussion:

Contributor: Ralph Robinson, Thames Pharma Partners - Tue, 13 Oct 2020 20:29:11 +0000